Interspecies scaling in pharmacokinetics: A novel whole-body physiologically based modeling framework to discover drug biodistribution mechanisms in vivo

Journal of Pharmaceutical Sciences

Volumn 101, Issue 3, 2012, Pages 1221-1241

  Hall, Cierra ^a   Lueshen, Eric ^a   Mošat', Andrej ^a   Linninger, Andreas A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Animal model; Biodistribution; Cyclosporin; Drug transport; Individualized drug therapy; Metabolic clearance; Nonlinear pharmacokinetics; Preclinical pharmacokinetics; Scaling; Whole body physiologically based pharmacokinetic model

Indexed keywords

CYCLOSPORIN A;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW; BLOOD VOLUME; CIRCULATION; DOSE RESPONSE; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG INDUSTRY; DRUG TRANSPORT; HAPLORHINI; HUMAN; IN VIVO STUDY; MATHEMATICAL ANALYSIS; NONHUMAN; PHARMACOKINETICS; SPECIES COMPARISON; SWINE;

EID: 84855909359     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22811     Document Type: Article

References (62)

1. Mathieu MP, Milne CP. 2008. New drug development: A regulatory overview. 8th ed. PAREXEL International Corporation, Waltham, MA, p 362.
2. Legg B, Rowland M. 1987. Cyclosporin: Measurement of fraction unbound in plasma. J Pharm Pharmacol 39(8):599-603.
3. Ursino M, Avanzolini G, Barbini P. 1992. Qualitative simulation of dynamic physiological models using the KEE environment. Artif Intell Med 4(1):53-73.
4. Buss WC, Stepanek J. 1993. Characterization of the inhibition of renal translation in the Sprague-Dawley rat following in vivo cyclosporin A. Int J Immunopharmacol 15(1):63-76.
5. Edginton AN, Theil FP, Schmitt W, Willmann S. 2008. Whole body physiologically-based pharmacokinetic models: Their use in clinical drug development. Expert Opin Drug Metab Toxicol 4(9):1143-1152.
6. Kawai R, Lemaire M, Steimer JL, Bruelisauer A, Niederberger W, Rowland M. 1994. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm 22(5):327-365.
7. Kawai R, Mathew D, Tanaka C, Rowland M. 1998. Physiologically based pharmacokinetics of cyclosporine A: Extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther 287(2):457-468.
8. Tanaka C, Kawai R, Rowland M. 2000. Dose-dependent pharmacokinetics of cyclosporin A in rats: Events in tissues. Drug Metab Dispos 28(5):582-589.
9. Gueorguieva I, Nestorov IA, Rowland M. 2006. Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: Diazepam case study. J Pharmacokinet Pharmacodyn 33(1):1-27.
10. Espié P, Tytgat D, Sargentini-Maier ML, Poggesi I, Watelet JB. 2009. Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 41(3):391-407.
11. Von Kleist M, Huisinga W. 2007. Physiologically based pharmacokinetic modelling: A sub-compartmentalized model of tissue distribution. J Pharmacokinet Pharmacodyn 34(6):789-806.
12. Von Kleist M, Huisinga W. 2009. Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: An example based on zidovudine. Eur J Pharm Sci 36(4-5):532-543.
13. Garg A, Balthasar JP. 2007. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34(5):687-709.
14. Laplanche R, Meno-Tetang GML, Kawai R. 2007. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. J Pharmacokinet Pharmacodyn 34(3):373-400.
15. Lüpfert C, Reichel A. 2005. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chem Biodivers 2(11):1462-1486.
16. Peters SA, Hultin L. 2008. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodyn 35(1):1-30.
17. Yates JWT. 2006. Structural identifiability of physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn 33(4):421-439.
18. Mahmood I, Balian JD. 1996. Interspecies scaling: Predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26(9):887-895.
19. Mahmood I. 2009. Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation. J Pharm Sci 98(10):3850-3861.
20. West GB, Brown JH, Enquist BJ. 1997. A general model for the origin of allometric scaling laws in biology. Science 276(5309):122-126.
21. West GB, Brown JH, Enquist BJ. 1999. The fourth dimension of life: Fractal geometry and allometric scaling of organisms. Science 284(5420):1677-1679.
22. Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS. 1992. The allometric approach for interspecies scaling of pharmacokinetic parameters. Comp Biochem Physiol C Comp Pharmacol 103(2):249-253.
23. Linninger AA, Xenos M, Sweetman B, Ponkshe S, Guo X, Penn R. 2009. A mathematical model of blood, cerebrospinal fluid and brain dynamics. J Math Biol 59(6):729-759.
24. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407-484.
25. Delp MD, Evans MV, Duan C. 1998. Effects of aging on cardiac output, regional blood flow, and body composition in Fischer-344 rats. J Appl Physiol 85(5):1813-1822.
26. Mošať A, Lueshen E, Hall C, Linninger AA. First principles pharmacokinetic modeling: A quantitative study on cyclosporin. J Pharmacokinet Pharmacodynam (in preparation).
27. Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW. 1999. Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 24(4):321-328.
28. Sadrieh N, Thomas PE. 1994. Characterization of rat cytochrome P450 isozymes involved in the covalent binding of cyclosporin A to microsomal proteins. Toxicol Appl Pharmacol 127(2):222-232.
29. Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou TC, Kahan BD. 2001. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 12(5):1059-1071.
30. Lindholm A, Henricsson S, Lind M, Dahlqvist R. 1988. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur J Clin Pharmacol 34(5):461-464.
31. Donaldson JR, Schnabel RB. 1987. Computational experience with confidence regions and confidence intervals for nonlinear least squares. Technometrics 29(1):67-82.
32. Petzold LR. 1989. Recent developments in the numerical solution of differential/algebraic systems. Comput Meth Appl Mech Eng 75(1-3):77-89.
33. Conn AR, Gould NIM, Toint PL. 1988. Global convergence of a class of trust region algorithms for optimization with simple bounds. Siam J Numer Anal 25(2):433-460.
34. Toint PL, Tomanos D, Weber-Mendonca M. 2009. A multilevel algorithm for solving the trust-region subproblem. Optim Methods Softw 24(2):299-311.
35. Zhang L, Xue C, Malcolm A, Kulkarni K, Linninger AA. 2006. Distributed system design under uncertainty. Ind Eng Chem Res 45(25):8352-8360.
36. Kulkarni K. 2007. Mathematical modeling, problem inversion and design of distributed chemical and biological systems. University of Illinois at Chicago.
37. Stephanopoulos GN, Aristidou AA, Nielsen J. 1998. Metabolic engineering: Principles and methodologies. Academic Press: San Diego, CA.
38. Nielsen J, Villadsen J, Lidén G. 2002. Bioreaction engineering principles. 2nd ed. Springer: New York, NY.
39. Palsson BO. 2006. Systems biology: Properties of reconstructed networks. 1st ed. Cambridge University Press: New York, NY.
40. Jia G, Stephanopoulos GN, Gunawan R. 2011. Parameter estimation of kinetic models from metabolic profiles: Two-phase dynamic decoupling method. Bioinformatics 27(14):1964-1970.
41. Fremming BD, Benson RE, Young RJ. 1955. Weights of organs in sixty-six male macaca mulatta monkeys. J Appl Physiol 8(2):155-158.
42. Upton RN. 2008. Organ weights and blood flows of sheep and pig for physiological pharmacokinetic modelling. J Pharmacol Toxicol Methods 58(3):198-205.
43. Williams LR, Leggett RW. 1989. Reference values for resting blood flow to organs of man. Clin Phys Physiol Meas 10(3):187-217.
44. Thurlby PL, Trayhurn P. 1980. Regional blood flow in genetically obese (Ob/Ob) mice. Pflugers Arch 385(3):193-201.
45. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093-1095.
46. Forsyth RP, Nies AS, Wyler F, Neutze J, Melmon KL. 1968. Normal distribution of cardiac output in the unanesthetized, restrined rhesus monkey. J Appl Physiol 25(6):736-741.
47. Mohammad Pervaiz NK, Garvin John, Steven Mell. 2010. Design of a drug delivery model for the rhesus monkey. LPPD technical report: University of Illinois at Chicago.
48. Weiss L, Haydock K, Pickren JW, Lane WW. 1980. Organ vascularity and metastatic frequency. Am J Pathol 101(1):101-114.
49. Hoffbrand BI, Forsyth RP. 1969. Validity studies of the radioactive microsphere method for the study of the distribution of cardiac output, organ blood flow, and resistance in the conscious rhesus monkey. Cardiovasc Res 3(4):426-432.
50. Van Woerkens lJ, Duncker DJ, Huigen RJ, Van der Giessen WJ, Verdouw PD. 1990. Redistribution of cardiac output caused by opening of arteriovenous anastomoses by a combination of azaperone and metomidate. Br J Anaesth 65(3):393-399.
51. Akhlaghi F, Ashley J, Keogh A, Brown K. 1999. Cyclosporine plasma unbound fraction in heart and lung transplantation recipients. Ther Drug Monit 21(1):8-16.
52. Yang H, Elmquist WF. 1996. The binding of cyclosporin A to human plasma: An in vitro microdialysis study. Pharm Res 13(4):622-627.
53. Akhlaghi F, Trull AK. 2002. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 41(9):615-637.
54. Schuurman HJ, Hengy JC, Ringers J, Vonderscher J, Schuler W, Jonker M. 1996. Neoral pharmacokinetics in cynomolgus monkeys: Relation to efficacy in renal allografting. Transplant Proc 28(6):3142-3144.
55. Schuurman HJ, Slingerland W, Mennninger K, Ossevoort M, Hengy JC, Dorobek B, Vonderscher J, Ringers J, Odeh M, Jonker M. 2001. Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: Relation to efficacy in kidney allografting. Transpl Int 14(5):320-328.
56. Cibulskyte D, Pedersen M, Jakobsen P, Hansen HE, Mortensen J. 2007. Pharmacokinetic characterization of a pig model of ciclosporin A nephrotoxicity following intravenous administration. Pharmacol Res 56(4):311-317.
57. Ptachcinski RJ, Venkataramanan R, Burckart GJ, Gray JA, Van Thiel DH, Sanghvi A, Rosenthal JT. 1987. Cyclosporine kinetics in healthy volunteers. J Clin Pharmacol 27(3):243-248.
58. Kimura S, Oshima K, Okuda S, Sato K, Sato M, Terasako K, Nakasone H, Kako S, Yamazaki R, Tanaka Y, Tanihara A, Higuchi T, Nishida J, Kanda Y. 2010. Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 45(6):1088-1094.
59. Lindholm A. 1991. Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 13(6):465-477.
60. Mager DE, Woo S, Jusko WJ. 2009. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24(1):16-24.
61. Silbernagl S, Despopoulos A. 2009. Color atlas of physiology. 6th ed. Stuttgart, New York: Thieme, pp xiii, 441.
62. Duff IS, Reid JK. 1993. MA48, a Fortran code for direct solution of sparse unsymmetric linear systems of equations. Rutherford Appleton Laboratory: Oxfordshire, United Kingdom, pp 1-62.